Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Biotech
BMS reports phase 3 win in multiple myeloma
With the study continuing to evaluate survival endpoints, it is unclear whether the drugmaker has the evidence needed to seek approval from the FDA.
Nick Paul Taylor
Sep 23, 2025 8:20am
AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer
Jul 10, 2025 9:01am
Biotech shares first data for in vivo CAR-T that attracted AZ
Jul 7, 2025 2:27pm
Pfizer-backed CellCentric secures $120M for ph. 3 myeloma trial
May 19, 2025 9:25am
C4T halts BRAF degrader work to save cash for cemsidomide
May 7, 2025 7:00am
British biotech CellCentric expands to Boston, plans hiring push
Apr 2, 2025 1:53pm
